Department of Internal Medicine-Oncology, the First Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming, 650032, People's Republic of China.
Department of Oncology, the First Affiliated Hospital of Kunming Medical University, Yunnan Province, No. 295 Xichang Road, Kunming, 650032, People's Republic of China.
BMC Med Genomics. 2021 Apr 30;14(1):117. doi: 10.1186/s12920-021-00965-4.
Studies on the XRCC3 rs1799794 polymorphism show that this polymorphism is involved in a variety of cancers, but its specific relationships or effects are not consistent. The purpose of this meta-analysis was to investigate the association between rs1799794 polymorphism and susceptibility to cancer.
PubMed, Embase, the Cochrane Library, Web of Science, and Scopus were searched for eligible studies through June 11, 2019. All analyses were performed with Stata 14.0. Subgroup analyses were performed by cancer type, ethnicity, source of control, and detection method. A total of 37 studies with 23,537 cases and 30,649 controls were included in this meta-analysis.
XRCC3 rs1799794 increased cancer risk in the dominant model and heterozygous model (GG + AG vs. AA: odds ratio [OR] = 1.04, 95% confidence interval [CI] = 1.00-1.08, P = 0.051; AG vs. AA: OR = 1.05, 95% CI = 1.00-1.01, P = 0.015). The existence of rs1799794 increased the risk of breast cancer and thyroid cancer, but reduced the risk of ovarian cancer. In addition, rs1799794 increased the risk of cancer in the Caucasian population.
This meta-analysis confirms that XRCC3 rs1799794 is related to cancer risk, especially increased risk for breast cancer and thyroid cancer and reduced risk for ovarian cancer. However, well-designed large-scale studies are required to further evaluate the results.
关于 XRCC3 rs1799794 多态性的研究表明，这种多态性与多种癌症有关，但具体的关系或影响并不一致。本荟萃分析的目的是探讨 rs1799794 多态性与癌症易感性的关系。
通过 6 月 11 日检索 PubMed、Embase、Cochrane 图书馆、Web of Science 和 Scopus，以获取合格的研究。所有分析均采用 Stata 14.0 进行。根据癌症类型、种族、对照来源和检测方法进行亚组分析。这项荟萃分析共纳入了 37 项研究，包括 23537 例病例和 30649 例对照。
XRCC3 rs1799794 在显性模型和杂合模型中增加了癌症风险（GG+AG 与 AA：比值比 [OR] = 1.04，95%置信区间 [CI] = 1.00-1.08，P = 0.051；AG 与 AA：OR = 1.05，95%CI = 1.00-1.01，P = 0.015）。rs1799794 的存在增加了乳腺癌和甲状腺癌的风险，但降低了卵巢癌的风险。此外，rs1799794 增加了白种人群患癌症的风险。
本荟萃分析证实，XRCC3 rs1799794 与癌症风险相关，特别是增加乳腺癌和甲状腺癌的风险，降低卵巢癌的风险。然而，需要进行设计良好的大规模研究来进一步评估结果。
